PD44-08 NOVEL DUAL TARGETING AKR1C3 AND AR/AR VARIANTS INHIBITS ANDROGEN SIGNALING AND OVERCOMES RESISTANCE TO ANTIANDROGEN TREATMENT

INTRODUCTION AND OBJECTIVE:AR/AR-V7 and AKR1C3 play key roles in prostate cancer progression and drive resistance to current therapies. Thus far, there are no clinically available therapies to spec...